RBC noted that while Avidity (RNA) is ahead on myotonic dystrophy type 1, or DM1, Dyne (DYN) may catch up with its Fab-ASO ...

On Tuesday, Oppenheimer reiterated its Outperform rating on Dyne Therapeutics (NASDAQ:DYN), maintaining a $60.00 price target, representing significant upside from the current price of $14.33.

Insiders who acquired US$1.06m worth of Dyne Therapeutics, Inc.'s ( NASDAQ:DYN ) stock at an average price of US$33.04... Shares of several biotech and biopharma names are under pressure on Monday ...

Dyne Therapeutics, Inc. is down 12.1% from its previous closing price of $9.420. During the last market session, Dyne ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

Dyne Therapeutics announced new long-term clinical data from the Phase 1/2 DELIVER trial of DYNE-251, a treatment for Duchenne muscular dystrophy (DMD) that has shown sustained functional ...

Dyne Therapeutics, Inc. engages in developing ... including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph.